Details of the Drug

General Information of Drug (ID: DM72JXH)

Drug Name
Losartan
Synonyms
Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 422.9
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.2 mL/min/kg [4]
Elimination
12% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.8 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.94873 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.37 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.048 mg/mL [3]
Chemical Identifiers
Formula
C22H23ClN6O
IUPAC Name
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Canonical SMILES
CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3961
ChEBI ID
CHEBI:6541
CAS Number
114798-26-4
DrugBank ID
DB00678
TTD ID
D0DD0K
VARIDT ID
DR00429
INTEDE ID
DR0984
ACDINA ID
D00153

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin II receptor type-1 (AGTR1) TT8DBY3 AGTR1_HUMAN Antagonist [6], [7], [8], [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [15]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin II receptor type-1 (AGTR1) DTT AGTR1 8.95E-01 1.34E-02 0.07
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Peptide transporter 1 (SLC15A1) DTP PEPT1 4.57E-01 2.15E-02 1.72E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Losartan
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Losartan and Aliskiren. Hypertension [BA00-BA04] [97]
Moexipril DM26E4B Major Increased risk of hyperkalemia by the combination of Losartan and Moexipril. Hypertension [BA00-BA04] [98]
Captopril DM458UM Major Increased risk of hyperkalemia by the combination of Losartan and Captopril. Hypertension [BA00-BA04] [98]
Perindopril DMOPZDT Major Increased risk of hyperkalemia by the combination of Losartan and Perindopril. Hypertension [BA00-BA04] [98]
Quinapril DMR8H31 Major Increased risk of hyperkalemia by the combination of Losartan and Quinapril. Hypertension [BA00-BA04] [98]
Lisinopril DMUOK4C Major Increased risk of hyperkalemia by the combination of Losartan and Lisinopril. Hypertension [BA00-BA04] [98]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Losartan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Nateglinide DMLK2QH Moderate Decreased metabolism of Losartan caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [99]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Losartan and Insulin-aspart. Acute diabete complication [5A2Y] [100]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Losartan caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [101]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Losartan caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Troleandomycin DMUZNIG Minor Decreased metabolism of Losartan caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [103]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Losartan and Cariprazine. Bipolar disorder [6A60] [104]
Alpelisib DMEXMYK Moderate Increased metabolism of Losartan caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [105]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Losartan and Olopatadine. Conjunctiva disorder [9A60] [106]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Losartan and Drospirenone. Contraceptive management [QA21] [107]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Losartan and Ardeparin. Coronary thrombosis [BA43] [98]
Mifepristone DMGZQEF Moderate Decreased metabolism of Losartan caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [108]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Losartan caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [109]
MK-8228 DMOB58Q Moderate Increased metabolism of Losartan caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [110]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Losartan and Selegiline. Depression [6A70-6A7Z] [111]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Losartan and Isocarboxazid. Depression [6A70-6A7Z] [111]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Losartan and Tranylcypromine. Depression [6A70-6A7Z] [111]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Losartan and OPC-34712. Depression [6A70-6A7Z] [104]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Losartan and Phenelzine. Depression [6A70-6A7Z] [111]
Primidone DM0WX6I Minor Increased metabolism of Losartan caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Phenobarbital DMXZOCG Minor Increased metabolism of Losartan caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Itraconazole DMCR1MV Moderate Decreased metabolism of Losartan caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [112]
Ketoconazole DMPZI3Q Minor Decreased metabolism of Losartan caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [103]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Losartan and Eplerenone. Heart failure [BD10-BD1Z] [113]
Rifampin DMA8J1G Moderate Increased metabolism of Losartan caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [114]
Rifapentine DMCHV4I Moderate Increased metabolism of Losartan caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [115]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Losartan and Procarbazine. Hodgkin lymphoma [2B30] [111]
Etravirine DMGV8QU Moderate Decreased metabolism of Losartan caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Losartan caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [117]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Losartan and Potassium chloride. Hypo-kalaemia [5C77] [118]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Losartan and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [119]
Amobarbital DM0GQ8N Minor Increased metabolism of Losartan caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [101]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Losartan and Propiomazine. Insomnia [7A00-7A0Z] [104]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Losartan and ITI-007. Insomnia [7A00-7A0Z] [104]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Losartan and Porfimer Sodium. Lung cancer [2C25] [120]
PF-06463922 DMKM7EW Moderate Increased metabolism of Losartan caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [117]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Losartan caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [121]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Losartan and Ozanimod. Multiple sclerosis [8A40] [111]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Losartan and Promethazine. Nausea/vomiting [MD90] [104]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Losartan caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [122]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Losartan and Safinamide. Parkinsonism [8A00] [111]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Losartan and Rasagiline. Parkinsonism [8A00] [111]
Abametapir DM2RX0I Moderate Decreased metabolism of Losartan caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [123]
Lefamulin DME6G97 Moderate Decreased metabolism of Losartan caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [124]
Enzalutamide DMGL19D Moderate Increased metabolism of Losartan caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [125]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Losartan and Levomepromazine. Psychotic disorder [6A20-6A25] [104]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Losartan caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [126]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Losartan and Quetiapine. Schizophrenia [6A20] [104]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Losartan and Mesoridazine. Schizophrenia [6A20] [104]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Losartan and Thioridazine. Schizophrenia [6A20] [104]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Losartan and Aripiprazole. Schizophrenia [6A20] [104]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Losartan and Iloperidone. Schizophrenia [6A20] [104]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Losartan and Paliperidone. Schizophrenia [6A20] [104]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Losartan and Molindone. Schizophrenia [6A20] [104]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Losartan and Thiothixene. Schizophrenia [6A20] [104]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Losartan and Trifluoperazine. Schizophrenia [6A20] [104]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Losartan and Risperidone. Schizophrenia [6A20] [104]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Losartan and Amisulpride. Schizophrenia [6A20] [104]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Losartan and Asenapine. Schizophrenia [6A20] [104]
Larotrectinib DM26CQR Moderate Decreased metabolism of Losartan caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [117]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Losartan caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [127]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Losartan and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [128]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Losartan and Insulin degludec. Type-1/2 diabete [5A10-5A11] [128]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Losartan and Methdilazine. Vasomotor/allergic rhinitis [CA08] [104]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Losartan and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [129]
⏷ Show the Full List of 64 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Methyl chloride E00114 6327 Other agent
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Losartan 100 mg tablet 100 mg Oral Tablet Oral
Losartan 25 mg tablet 25 mg Oral Tablet Oral
Losartan 50 mg tablet 50 mg Oral Tablet Oral
Losartan Potassium 25mg tablet 25mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
7 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
8 Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol. 2000 Feb;119(2-3):189-97.
9 Characterization of [3H]losartan receptors in isolated rat glomeruli. Eur J Pharmacol. 1993 Oct 15;247(2):193-8.
10 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
11 Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
15 Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
25 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
26 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
27 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
28 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
29 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
30 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
31 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
32 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
33 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
34 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
35 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
36 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
37 Drug Interactions Flockhart Table
38 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
39 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
40 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
41 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
42 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
43 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
44 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
45 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
46 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
47 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
48 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
49 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
50 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
51 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
52 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
53 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
54 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
55 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
56 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
57 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
58 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
59 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
60 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
61 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
62 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
63 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
64 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
65 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
66 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
67 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
68 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
69 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
70 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
71 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
72 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
73 Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
74 In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
75 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
76 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
77 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
78 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
79 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
80 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
81 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
82 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
83 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
84 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
85 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
86 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
87 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
88 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
89 Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
90 Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
91 Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
92 The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
93 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
94 Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
95 Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.
96 Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26.
97 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
98 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
100 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
101 Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mcwilliams EJ, Mccrea JB "Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite e-3174." Clin Pharmacol Ther 59 (1996): 268-74. [PMID: 8653989]
102 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
103 Product Information. Cozaar (losartan). Merck & Co, Inc, West Point, PA.
104 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
105 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
106 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
107 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
108 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
109 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
110 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
111 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
112 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
113 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
114 Product Information. Cozaar (losartan). Merck &amp Co, Inc, West Point, PA.
115 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
116 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
117 Cerner Multum, Inc. "Australian Product Information.".
118 Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12. [PMID: 6744599]
119 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
120 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
121 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
122 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
123 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
124 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
125 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
126 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
127 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
128 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
129 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.